User profiles for Mads Israelsen

Mads Israelsen

Post Doc, Odense University Hospital
Verified email at rsyd.dk
Cited by 925

Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta‐analysis

AD Fialla, M Israelsen, O Hamberg, A Krag… - Liver …, 2015 - Wiley Online Library
Background & Aims Patients with cirrhosis and alcoholic hepatitis are often malnourished
and have a superimposed stress metabolism, which increases nutritional demands. We …

Terlipressin versus other vasoactive drugs for hepatorenal syndrome

M Israelsen, A Krag, AS Allegretti… - Cochrane Database …, 2017 - cochranelibrary.com
Background Hepatorenal syndrome is defined as severe renal failure occurring in people
with cirrhosis and ascites. Systematic reviews of randomised clinical trials found that, …

Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome

AS Allegretti, M Israelsen, A Krag… - Cochrane Database …, 2017 - cochranelibrary.com
Background Hepatorenal syndrome is a potentially reversible renal failure associated with
severe liver disease. The disease is relatively common among people with decompensated …

[HTML][HTML] Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease

…, S Johansen, M Kjærgaard, KP Lindvig, M Israelsen… - Journal of …, 2021 - Elsevier
Background & aims Alcohol is the most common cause of liver-related mortality and morbidity.
We therefore aimed to assess and compare the prognostic performance of elastography …

Effect of calorie-unrestricted low-carbohydrate, high-fat diet versus high-carbohydrate, low-fat diet on type 2 diabetes and nonalcoholic fatty liver disease: a …

…, K Højlund, MS Thiele, M Israelsen… - Annals of Internal …, 2023 - acpjournals.org
Background: It remains unclear if a low-carbohydrate, high-fat (LCHF) diet is a possible
treatment strategy for type 2 diabetes mellitus (T2DM), and the effect on nonalcoholic fatty liver …

[HTML][HTML] Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease

…, JM Jensen, CD Hansen, S Johansen, M Israelsen… - Journal of …, 2023 - Elsevier
Background & Aims There is a need for accurate biomarkers of fibrosis for population screening
of alcohol-related and non-alcoholic fatty liver disease (ALD, NAFLD). We compared the …

[HTML][HTML] Metabolic and genetic risk factors are the strongest predictors of severity of alcohol-related liver fibrosis

M Israelsen, HB Juel, S Detlefsen, BS Madsen… - Clinical …, 2022 - Elsevier
Background & Aims Individual risk for developing alcohol-related liver disease (ALD) varies
greatly. We hypothesized that metabolic risk factors and genetic polymorphisms predict …

Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial

M Israelsen, BS Madsen, N Torp… - The Lancet …, 2023 - thelancet.com
Background Alcohol is the leading cause of liver-related mortality worldwide. The gut–liver
axis is considered a key driver in alcohol-related liver disease. Rifaximin-α improves gut-…

Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study

…, R Hernández-Ibañez, A Ikram, S Incicco, M Israelsen… - The Lancet, 2023 - thelancet.com
Background Liver cirrhosis is a major cause of death worldwide. Cirrhosis develops after a
long asymptomatic period of fibrosis progression, with the diagnosis frequently occurring late, …

MetALD: new opportunities to understand the role of alcohol in steatotic liver disease

M Israelsen, N Torp, S Johansen, M Thiele… - The Lancet …, 2023 - thelancet.com
For many years non-alcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD)
have been considered as two biologically and clinically distinct conditions. According …